DEVELOPMENT AND CHARACTERIZATION OF NANOPARTICLES OF GLIBENCLAMIDE BY SOLVENT DISPLACEMENT METHOD

被引:0
作者
Dora, Chander Parkash [1 ]
Singh, Shailendra Kumar [1 ]
Kumar, Sanjeev [1 ]
Datusalia, Ashok Kumar [1 ]
Deep, Aakash [1 ]
机构
[1] Guru Jambheshwar Univ Sci & Technol, Dept Pharmaceut Sci, Div Drug Delivery & Res, Hisar 125001, Haryana, India
来源
ACTA POLONIAE PHARMACEUTICA | 2010年 / 67卷 / 03期
关键词
nanoparticles; solvent displacement; glibenclamide; Eudragit L100; alloxan; IN-VITRO; DISSOLUTION CHARACTERISTICS; INVITRO DISSOLUTION; PLGA NANOPARTICLES; BETA-CYCLODEXTRIN; VIVO EVALUATION; PARTICLE-SIZE; DRUG; RELEASE; NANOSUSPENSIONS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to formulate nanoparticles (NPs) containing glibenclamide (GB) prepared with Eudragit L100 to achieve a better release profile suitable for per oral administration with enhanced efficacy. The NPs were prepared by solvent displacement method. The influence of various formulation factors (drug : polymer ratio and concentration of surfactants) on particle size, size distribution, zeta potential. drug loading and encapsulation efficiency were investigated. Drug : polymer ratio was observed to be important parameter influencing mean particle size, beside others. Encapsulation efficiency and drug loading capacity were found to be increased as drug concentration increases with respect to polymer. Addition of surfactants showed a promising result in decreasing particle size of NPs. Dissolution study revealed increased release of GB from NPs. Transmission electron microscopy (TEM) study revealed spherical morphology of the developed NPs. Differential scanning calorimetry (DSC) studies confirmed phase transition behavior of NPs. they also showed very significant change in saturation solubility in comparison with pure drug. Developed NPs revealed a decreased and enhanced bioavailability and hence superior activity as compared to plain GB in alloxan-induced diabetic rabbit model. The developed NPs could reduce close frequency. decrease side effects. and improve patient compliance.
引用
收藏
页码:283 / 290
页数:8
相关论文
共 42 条
[1]  
ARNQVIST HJ, 1983, ANN CLIN RES, V15, P21
[2]  
BORCHERT HH, 1976, PHARMAZIE, V31, P307
[3]   CORRELATIONS BETWEEN INVITRO DISSOLUTION, INVIVO BIOAVAILABILITY AND HYPOGLYCEMIC EFFECT OF ORAL GLIBENCLAMIDE [J].
CHALK, JB ;
PATTERSON, M ;
SMITH, MT ;
EADIE, MJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 (02) :177-182
[4]   FORMULATION, PREPARATION AND DISSOLUTION CHARACTERISTICS OF PROPRANOLOL HYDROCHLORIDE MICROSPHERES [J].
CHIAO, CSL ;
PRICE, JC .
JOURNAL OF MICROENCAPSULATION, 1994, 11 (02) :153-159
[5]  
CHOWDARY KPR, 2004, AAPS PHARM SCITECH, V4, P1
[6]  
Davis SN., 2001, GOODMAN GILMANS PHAR, V10th, P1701
[7]   Preparation and in vitro/in vivo evaluation of gliclazide loaded Eudragit nanoparticles as a sustained release carriers [J].
Devarajan, Padma V. ;
Sonavane, Ganeshchandra S. .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2007, 33 (02) :101-111
[8]   In vitro evaluation of a system for pH-controlled peroral delivery of metformin [J].
Di Colo, G ;
Falchi, S ;
Zambito, Y .
JOURNAL OF CONTROLLED RELEASE, 2002, 80 (1-3) :119-128
[9]   In vitro and in vivo evaluation of carbamazepine-loaded enteric microparticles [J].
Dong, W. Y. ;
Maincent, P. ;
Bodmeier, R. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 331 (01) :84-92
[10]  
DOUGLAS SJ, 1987, CRIT REV THER DRUG, V3, P233